Advertisement
"This is an important strategic milestone in the development ofReviroc(TM) and we are very pleased with the orphan drug designationsreceived from the FDA," says Dr. Manja Bouman, Chief Executive Officer ofKiadis Pharma.
Advertisement
The FDA's orphan drug designation is reserved for new therapies beingdeveloped to treat diseases or conditions that affect fewer than 200,000people in the United States. The orphan drug designation provides for anaccelerated review process, tax benefits, exemption from user fees and aseven-year period of market exclusivity in the US after product approval.
About Reviroc(TM)
Reviroc(TM) is being developed as a treatment that eliminates bloodcancer cells from autologous transplants for patients with end stage bloodcancer. An autologous transplant uses the patient's own bone marrow to serveas a graft. Bone marrow transplants are broadly recognized as a treatmentoption for patients suffering from blood cancers, such as leukemia andlymphoma. One of the limitations of autologous bone marrow transplantationsis the high relapse rate associated with this treatment. This is often causedby the presence of cancer cells in the transplant. Reviroc(TM) has beendeveloped to remove tumor cells from the graft.
About Kiadis Pharma
Kiadis Pharma is an oncology focused biopharmaceutical developmentcompany with cell based products in clinical development. The companydevelops products that offer novel treatment options for terminally illcancer patients and address significant unmet medical needs. The key focusindication for Kiadis Pharma is limitations and complications of bone marrowtransplantation procedures performed in blood cancer patients. Kiadis Pharmais headquartered in Amsterdam, The Netherlands with facilities in Groningen,The Netherlands and Montreal, Canada. For more information about KiadisPharma, please visit http://www.kiadis.com.
SOURCE Kiadis Pharma
